Clinical outcomes with triple tandem brachytherapy for medically inoperable endometrial cancer in a high-risk patient population
Brachytherapy · 2026
DOI: 10.1016/j.brachy.2025.10.010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brachytherapy, 2026. Verfasst von Michael Jason Gutman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation & Cellular Oncology, University of Chicago, Chicago, IL. Hauptthemen laut MEDLINE: Endometrial Neoplasms, Brachytherapy. Die Arbeit nennt 41 Literaturangaben.
Abstract (Originalsprache)
PURPOSE: The purpose of this study is to evaluate clinical outcomes for medically inoperable endometrial cancer (MIEC) patients treated with triple tandem brachytherapy (TTB) ± external beam radiation therapy (EBRT). METHODS: This single institution retrospective review analyses MIEC patients treated definitively with TTB ± EBRT from 2014 to 2021. FIGO stage I-II with Grade 1-2 histology were considered low-risk endometrial cancer (LREC) and FIGO stage III-IVB and/or any Grade 3 endometrioid carcinoma, clear cell, or serous carcinoma were considered high-risk endometrial cancer (HREC). Planning parameters for target volume(s) and OARs (organs at risk) were per ABS guidelines. Overall survival (OS) and local failure-free survival (LFFS) were estimated by Kaplan-Meier analysis. Local control (LC), acute and late toxicities were evaluated clinically. RESULTS: Of 26 patients, 92.3% (n = 24) received TTB + EBRT. The median age at diagnosis was 66.5 years (40.5-88.7 years). Median follow up was 41.1 months (1.7-109.9 months). Median prescribed doses to the uterus were 45 Gy (0-50.4 Gy) for EBRT and 22.25 Gy (18-49.1 Gy) for TTB. 53.8% (n = 14) had LREC and 46.2% (n = 12) had HREC. 88.5% had endometrioid histology. The median OS for the entire cohort was 43.5 months with no difference for the LREC and HREC (p = 0.563). LC was superior (p = 0.032) in LREC patients (100% 4-year LFFS) with all recurrences occurring in the HREC cohort (1-/4-year LFFS 90.9%/62.3%). Late toxicities > Grade 2 were: Grade 2 GU (n = 2) and Grade 2 GI (n = 1). CONCLUSIONS: Definitive TTB ± EBRT for MIEC patients was associated with excellent LFFS and acceptable toxicity rates.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Radiation & Cellular Oncology, University of Chicago, Chicago, IL.
- Department of Radiation Oncology, Emory University, Atlanta, GA.
- Department of Radiation & Cellular Oncology, University of Chicago, Chicago, IL; Department of Radiation Oncology, University of IL Chicago, Chicago, IL.
- Department of Radiation & Cellular Oncology, University of Chicago, Chicago, IL. Electronic address: Yasmin.hasan@uchicagomedicine.org.
Zitieren
APA
Gutman, M. J., Wu, T., Sivananthan, A., Al-Hallaq, H., Son, C., & Hasan, Y. (2026). Clinical outcomes with triple tandem brachytherapy for medically inoperable endometrial cancer in a high-risk patient population. Brachytherapy. https://doi.org/10.1016/j.brachy.2025.10.010
Vancouver
Gutman MJ, Wu T, Sivananthan A, Al-Hallaq H, Son C, Hasan Y. Clinical outcomes with triple tandem brachytherapy for medically inoperable endometrial cancer in a high-risk patient population. Brachytherapy. 2026. doi:10.1016/j.brachy.2025.10.010
BibTeX
@article{Gutman2026,
author = {Gutman, Michael Jason and Wu, Tianming and Sivananthan, Aranee and Al-Hallaq, Hania and Son, Christina and Hasan, Yasmin},
title = {Clinical outcomes with triple tandem brachytherapy for medically inoperable endometrial cancer in a high-risk patient population},
journal = {Brachytherapy},
year = {2026},
doi = {10.1016/j.brachy.2025.10.010}
}
EUVIMED